Could 2 HPV vaccine doses be enough for women 27-45? new trial aims to find out.

NCT ID NCT05672927

Recruiting now Prevention Sponsor: The University of Texas Medical Branch, Galveston Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the immune response from 2 doses versus the standard 3 doses of the HPV vaccine in women aged 27-45. About 618 participants will be randomly assigned to receive either 2 or 3 doses, and their antibody levels will be checked over 12 months. If 2 doses prove noninferior, it could lead to a simpler vaccination schedule for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 9-valent HPV vaccine
What this could lead to: If 2 doses work as well as 3, it could simplify HPV vaccination for women in this age group, making it easier and cheaper to get protected.
What could go wrong: This is a Phase 4 study, but it only measures short-term antibody responses, not long-term cancer prevention. The results may not change current guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV INFECTION HUMAN PAPILLOMAVIRUS IMMUNIZATION

Contacts and locations

Locations

University of Texas Medical Branch
RECRUITING

Galveston, Texas, 77555, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.